{"id":"W1521568442","doi":"10.1002/ddr.21118","title":"Coagulation Assays in Patients with New Oral Anticoagulants (<scp>NOACs</scp>): Why? When?","year":2013,"lang":"en","type":"article","venue":"Drug Development Research","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Dabigatran; Rivaroxaban; Apixaban; Partial thromboplastin time; Fondaparinux; Pharmacology; Clotting time; Anticoagulant; Thrombin time; Prothrombin time; Medicine; Coagulation testing; Thromboplastin; Drug; Coagulation; Discovery and development of direct thrombin inhibitors; Direct thrombin inhibitor; Chemistry; Thrombin; Internal medicine; Warfarin; Thrombosis; Platelet; Atrial fibrillation; Venous thromboembolism","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001066281,0.000199131,0.0003714364,0.0007074681,0.0001606173,0.0001347329,0.0001634778,0.00008620168,0.0003836053],"category_scores_gemma":[0.0003644462,0.000151768,0.00003858516,0.0007389556,0.00006335395,0.0003755914,0.0001728147,0.0002965737,0.0008628092],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002492771,"about_ca_system_score_gemma":0.0003580322,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005692174,"about_ca_topic_score_gemma":0.0001896909,"domain_scores_codex":[0.9967815,0.0001426399,0.0004340259,0.0003965887,0.001584983,0.0006602403],"domain_scores_gemma":[0.9986748,0.0002691529,0.00007719654,0.0002844715,0.000429845,0.0002644973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005881934,0.00004522572,0.9435369,0.00004836051,0.00006199072,0.000005455322,0.001050846,0.00001321785,0.00005008817,0.0001093134,0.04325681,0.01176292],"study_design_scores_gemma":[0.003374995,0.00007413716,0.9590704,0.0001070885,0.00001121315,5.045339e-7,0.0002774876,0.000153413,0.0005933628,0.0002737168,0.03597494,0.00008868959],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913273,0.00003479745,0.0002424777,0.002001441,0.0000937169,0.00184017,8.252644e-7,0.00006389697,0.004395338],"genre_scores_gemma":[0.9685595,0.00001073887,0.005193364,0.0001780048,0.0001518055,0.00001971507,0.0002126729,0.00003463458,0.02563953],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02276781,"threshold_uncertainty_score":0.9999151,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1032542157200367,"score_gpt":0.3556670945648224,"score_spread":0.2524128788447856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}